Centrifugal Filter Device for Detection of Rare Cells With Immuno-Binding

被引:4
作者
Chen, Chih-Chung [1 ]
Chen, Yu-An [1 ]
Yao, Da-Jeng [1 ]
机构
[1] Natl Tsing Hua Univ, Inst NanoEngn & MicroSyst, Hsinchu 300, Taiwan
关键词
Centrifugal device; circulating tumor cells (CTCs); immuno-binding; CIRCULATING TUMOR-CELLS; RESISTANT PROSTATE-CANCER; METASTATIC BREAST-CANCER; PROGNOSTIC-SIGNIFICANCE; LUNG-CANCER; END-POINTS; BLOOD; TRIAL; SURVIVAL; PLATFORM;
D O I
10.1109/TNB.2015.2485298
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Many investigations have shown circulating tumor cells (CTCs) to serve as a significant biomarker of cancer progression and for cancer treatment. Multiple blood samples detection of CTCs during a course of treatment might facilitate a choice by a medical doctor of an effective drug and a treatment for particular patients. A simple and cost-effective method to identify the trend of decreasing CTCs during a treatment with various therapies is in great demand. A novel multilayer, concentric filter device combined with an immune-binding method enables the enrichment and detection of rare cells in a mass cell population with a separation based on size. Such separation implemented with a filter is among the most efficient, simple and inexpensive methods to isolate cells, but its main disadvantages are clogging, deformation of cells, and a requirement of a significant difference of size between targeted rare cells and normal cells. We designed a concentric filter device and an immune-binding method to create a significant size difference of target cells, and increased the efficiency of separation to identify rare cells with a simple miniature centrifuge in the laboratory. The enrichment of target rare cells from a mass cell population and the detection were demonstrated on mixing targeted MCF-7 blast cancer cells and Jurkat blood cells in ratio 1: 1 000 000. The device is prospectively applicable for the detection of circulating tumor cells in a clinical application.
引用
收藏
页码:864 / 869
页数:6
相关论文
共 23 条
[11]   Deformability considerations in filtration of biological cells [J].
Kuo, Jason S. ;
Zhao, Yongxi ;
Schiro, Perry G. ;
Ng, Laiying ;
Lim, David S. W. ;
Shelby, J. Patrick ;
Chiu, Daniel T. .
LAB ON A CHIP, 2010, 10 (07) :837-842
[12]   Biochip for separating fetal cells from maternal circulation [J].
Mohamed, Hisham ;
Turner, James N. ;
Caggana, Michele .
JOURNAL OF CHROMATOGRAPHY A, 2007, 1162 (02) :187-192
[13]   Immunomagnetic quantification of circulating tumor cells as a prognostic factor of androgen deprivation responsiveness in patients with hormone naive metastatic prostate cancer [J].
Okegawa, Takatsugu ;
Nutahara, Kikuo ;
Higashihara, Eiji .
JOURNAL OF UROLOGY, 2008, 180 (04) :1342-1347
[14]   Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience [J].
Olmos, D. ;
Arkenau, H. -T. ;
Ang, J. E. ;
Ledaki, I. ;
Attard, G. ;
Carden, C. P. ;
Reid, A. H. M. ;
A'Hern, R. ;
Fong, P. C. ;
Oomen, N. B. ;
Molife, R. ;
Dearnaley, D. ;
Parker, C. ;
Terstappen, L. W. M. M. ;
de Bono, J. S. .
ANNALS OF ONCOLOGY, 2009, 20 (01) :27-33
[15]   Highly Efficient Assay of Circulating Tumor Cells by Selective Sedimentation with a Density Gradient Medium and Microfiltration from Whole Blood [J].
Park, Jong-Myeon ;
Lee, June-Young ;
Lee, Jeong-Gun ;
Jeong, Hyoyoung ;
Oh, Jin-Mi ;
Kim, Yeon Jeong ;
Park, Donghyun ;
Kim, Minseok S. ;
Lee, Hun Joo ;
Oh, Jin Ho ;
Lee, Soo Suk ;
Lee, Won-Yong ;
Huh, Nam .
ANALYTICAL CHEMISTRY, 2012, 84 (17) :7400-7407
[16]   High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients [J].
Pierga, J. -Y. ;
Hajage, D. ;
Bachelot, T. ;
Delaloge, S. ;
Brain, E. ;
Campone, M. ;
Dieras, V. ;
Rolland, E. ;
Mignot, L. ;
Mathiot, C. ;
Bidard, F. -C. .
ANNALS OF ONCOLOGY, 2012, 23 (03) :618-624
[17]   Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non-Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib [J].
Punnoose, Elizabeth A. ;
Atwal, Siminder ;
Liu, Weiqun ;
Raja, Rajiv ;
Fine, Bernard M. ;
Hughes, Brett G. M. ;
Hicks, Rodney J. ;
Hampton, Garret M. ;
Amler, Lukas C. ;
Pirzkall, Andrea ;
Lackner, Mark R. .
CLINICAL CANCER RESEARCH, 2012, 18 (08) :2391-2401
[18]   Circulating tumour cells in breast cancer [J].
Ring, A ;
Smith, IE ;
Dowsett, M .
LANCET ONCOLOGY, 2004, 5 (02) :79-88
[19]   Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data [J].
Scher, Howard I. ;
Jia, Xiaoyu ;
de Bono, Johann S. ;
Fleisher, Martin ;
Pienta, Kenneth J. ;
Raghavan, Derek ;
Heller, Glenn .
LANCET ONCOLOGY, 2009, 10 (03) :233-239
[20]   Microdevice for the isolation and enumeration of cancer cells from blood [J].
Tan, Swee Jin ;
Yobas, Levent ;
Lee, Gabriel Yew Hoe ;
Ong, Choon Nam ;
Lim, Chwee Teck .
BIOMEDICAL MICRODEVICES, 2009, 11 (04) :883-892